Email this article 
Post a Comment 
Involved-site radiation therapy by volumetric modulated arc therapy versus 3D- conformal radiotherapy for treatment of stages I and II supra-diaphragmatic Hodgkin’s lymphoma
Abstract
Purpose: Based on the observation that recurrences of Hodgkin's lymphoma (HL) typically occur in sites of initial nodal involvement the need to concise radiotherapy to only involved nodes that was termed as involved nodal radiotherapy (INRT) or of involved site lymph nodes, involved-site radiation therapy (ISRT) is starting to be widely accepted to use in early stage HL. We aimed in our study to compare between volumetric modulated arc therapy (VMAT) and 3D-conformal radiotherapy (3D-CRT) in radiation of early stage supra-diaphragmatic HL.
Methods: The clinical and dosimetric data of 34 patients affected with stages I and II supra-diaphragmatic HL, treated between January 2011 and September 2015 with combined modalities therapy in a single institution were analyzed. Patients received 2-8 cycles of combination chemotherapy ABVD (Adriamycin, Bleomycin, Vinblastine & Dacarbazine) on days 1 and 15 repeated every 28 days. The clinical target volume (CTV) was contoured based on the pre-chemotherapy CT and PET-CT scans. Modification of the CTV was done according to post-chemotherapy anatomical changes. The radiation dose given was 30 Gy/15 fractions.
Results: After a median follow up period of 30 months, the progression free survival (PFS) and overall survival (OS) in both groups were 100%. Oropharengeal mucositis was the commonest toxicity in both groups. There was no statistically significant deference between the acute radiation toxicities in both groups. The Dmean valuefor lung was higher in 3D-CRT than VMAT (12.0 ± 6.1 Gy vs. 9.9 Gy ± 8.6 Gy). For the breasts volume, the V5Gy was slightly higher for 3D-CRT compared with VMAT at, 7.6% and 6.5% respectively. For the heart, V5Gy and V10Gy valueswere higher for the RA than for 3D-CRT accounting for (51.9 ± 28.9%) and (41.0 ± 24.6%) versus (40.0 ± 25.9% and 30.7 ± 22.5%) respectively. Thyroid gland mean dose was lower for VMAT (21.8 ± 7.7 Gy) than for 3D-CRT (26.8 Gy ± 4.1 Gy) but did not reach statistically significant value (P = 0.06).
Conclusion: Involved-site VMAT technique is safe and effective in term of providing excellent local control and survival following ABVD-based chemotherapy.
Keywords
Full Text:
PDFReferences
Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854-62.
Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21:3431-9.
Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484-94.
Shahidi M, Kamangari N, Ashley S, et al. Site of relapse after chemotherapy alone for stage I and II Hodgkin's disease. Radiother Oncol. 2006;78:1-5.
Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. J Clin Oncol. 2008; 26:5170-4.
Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79:270-7.
Campbell BA, Hornby C, Cunninghame J, et al. Minimizing critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. Ann Oncol. 2012: 23:1259-66.
Daoud MA, Saleh YM, Habash AS. Simultaneous integrated boost by RapidArc therapy plus temozolomide for treatment of patients with glioblastoma multiform: A single institution experience. Int J Cancer Ther Oncol. 2015;3(3):3314.
Teoh M, Clark CH, Wood K, et al. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol. 2011;84(1007):967-96.
Weber DC, Peguret N, Dipasquale G, Cozzi L. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: A comparative planning study. Int J Radiat Oncol Biol Phys. 2009;75:1578-86.
Fogarty GB, Ng D, Liu G, et al. Volumetric modulated arc therapy is superior to conventional intensity modulated radiotherapy - a comparison among prostate cancer patients treated in an Australian center. Radiat Oncol. 2011;6:108.
Lee YK, Bedford JL, Taj M, Saran FH. Use of volumetric-modulated arc therapy for treatment of Hodgkin lymphoma. Med Dosim. 2013;38(4):372-5.
Girinsky T, Specht L, Ghalibafian M, et al. The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol. 2008;88(2):202–10.
Girinsky T, Ghalibafian M, Bonniaud G, et al. Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy. Radiother Oncol. 2007;85(2):178-87.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phy. 1995;31(1):1341–6.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
Ghalibafian M, Beaudre A, Girinsky T. Heart and coronary artery protection in patients with mediastinal Hodgkin lymphoma treated with intensity modulated radiotherapy: Dose constraints to virtual volumes or to organs at risk? Radiother Oncol. 2008;87(1):82–8.
Cella L, Liuzzi R, Conson M, et al. Dosimetric predictors of asymptomatic heart valvular dysfunction following mediastinal irradiation for Hodgkin’s lymphoma. Radiat Oncol. 2011;101:316–21.
Lu NN, Li YX, Wu RY, et al. Dosimetric and clinical outcomes of involved-field intensity modulated radiotherapy after chemotherapy for early stage Hodgkin’s lymphoma with mediastinal involvement. Int J Radiat Oncol Biol Phys. 2012;84:210-6.
Filippi AA, Ciammella P, Piva C, et al. Involved-site image-guided intensity modulated versus 3d conformal radiation therapy in early stage supradiaphragmatic Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys. 2014;89:370-5.
Koeck J, Abo-Madyan Y, Lohr F, et al. Radiotherapy for early mediastinal Hodgkin Lymphoma according to the German Hodgkin Study Group (GHSG): The roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83:268–76.
Findra C, Filippi AR, Catuzzo P, et al. Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin’s lymphoma: Dosimetric comparison and clinical considerations. Radiat Oncol. 2012;7:186.
Girinsky T, Pichenot C, Beaudre A, et al. Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin’s disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys. 2006;64:218–26.
Filippi AR, Ragona R, Fusella M, et al. Changes in breast cancer risk associated with different volumes, doses and techniques in female Hodgkin’s lymphoma patients treated with supra-diaphragmatic radiotherapy. Pract Radiat Oncol. 2013;3:216-22.
Maraldo MV, Brodin NP, Aznar MC, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early stage mediastinal Hodgkin’s lymphoma. Ann Oncol. 2013;24:2113-8.
Cella L, Conson M, Pressello MC, et al. Hodgkin's lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms. Radiat Oncol. 2013;8:22.
DOI: http://dx.doi.org/10.14319/ijcto.43.13
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.
Number of visits since October, 2013